Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:03:54.970Z.
Calculation as of: 2026-10-06T17:03:54.970Z.
Quote observation: 2026-10-06T17:00:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd9bff75293b0061b415f76424971e71050022ba1ca13a61eeb09eda3fdb1614
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.47B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49B
EV/EBITDA Ratio
8.89x
TTM Avg
11.44x
3Y Avg
12.12x
5Y Avg
11.37x
Market Cap
$1.50B
EV/EBITDA Ratio
71.88x
TTM Avg
329.18x
3Y Avg
230.60x
5Y Avg
237.22x
Market Cap
$1.46B
EV/EBITDA Ratio
8.99x
TTM Avg
18.38x
3Y Avg
16.03x
5Y Avg
16.85x
Market Cap
$1.44B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
EV/EBITDA Ratio
N/A
TTM Avg
5.67x
3Y Avg
5.67x
5Y Avg
5.67x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.47B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 8.89x | 11.44x | 12.12x | 11.37x |
| Certara, Inc. (CERT)vs › | $1.46B | 26.52x | 16.63x | 66.61x | 73.09x |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 71.88x | 329.18x | 230.60x | 237.22x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.99x | 18.38x | 16.03x | 16.85x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | N/A | 5.67x | 5.67x | 5.67x |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | N/A | 37.36x | 37.36x | 37.36x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
